IL1A Antikörper (Biotin)

Produktnummer ABIN7608282

Dieses Anti-IL1A-Antikörper ist ein Human Chimeric-Antikörper zur Detektion von IL1A in FACS. Geeignet für Human.

Kurzübersicht für IL1A Antikörper (Biotin) (ABIN7608282)

Target: IL1A (Interleukin 1 alpha (IL1A))

Reaktivität: Human

Wirt: Human, Kaninchen

Klonalität: Chimeric

Konjugat: Dieser IL1A Antikörper ist konjugiert mit Biotin

Applikation: Flow Cytometry (FACS)

Klon: 4G2

Produktdetails anti-IL1A Antikörper (Biotin)

Verwendungszweck: Biotinylated Anti-IL1A antibody(4G2), IgG1 Chimeric mAb

Aufreinigung: Purified from cell culture supernatant by affinity chromatography

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Flow Cyt 1/100

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Haltbarkeit: 12 months

Details zu IL1A

Target: IL1A (Interleukin 1 alpha (IL1A))

Andere Bezeichnung: IL1A

Hintergrund: The protein encoded by this gene is a member of the interleukin 1 cytokine family. This cytokine is a pleiotropic cytokine involved in various immune responses, inflammatory processes, and hematopoiesis. This cytokine is produced by monocytes and macrophages as a proprotein, which is proteolytically processed and released in response to cell injury, and thus induces apoptosis. This gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2. It has been suggested that the polymorphism of these genes is associated with rheumatoid arthritis and Alzheimer's disease. [provided by RefSeq, Jul 2008]

UniProt: P01583

Pathways: NF-kappaB Signalweg, Autophagie, Cancer Immune Checkpoints